Clinical efficacy of SARS‐CoV‐2 Omicron ‐neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency

Ähnliche Einträge

• Empowering SARS‐CoV‐2 variant neutralization with a bifunctional antibody engineered with tandem heptad repeat 2 peptides
  von: Ji Woong Kim, et al.
  Veröffentlicht: (2024)
• Mucosal antibody response and SARS‐CoV‐2 shedding in patients with COVID‐19 related olfactory dysfunction
  von: Shilpee Sharma, et al.
  Veröffentlicht: (2024)
• Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023
  von: Marie‐Laure Chaix, et al.
  Veröffentlicht: (2024)
• Malaria and other infections induce polyreactive antibodies that impact SARS‐CoV‐2 seropositivity estimations in endemic settings
  von: Ruth Aguilar, et al.
  Veröffentlicht: (2024)
• SARS‐CoV‐2 reinfection broadens the antibody responses and promotes the phenotypic differentiation of virus‐specific memory T cells in adolescents
  von: Xin‐Jing Zhao, et al.
  Veröffentlicht: (2024)